TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01377415
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine 5 mg/ml infusion 2 ml/h 48 h
Study: NCT00439166
Drug: rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
Study: NCT00439166
Drug: Placebo matched to Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
Study: NCT03634137
Drug: Afamelanotide Group 1
DrugBank: Afamelanotide (DB04931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
Study: NCT04439006
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00174447
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
Study: NCT01006525
Drug: zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo or zolpidem (10mg)daily for one year
Study: NCT03988010
Drug: Amantadine Sulfate
Normalized name: amantadine sulfate
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg/500ml i.v. solution for infusion
Study: NCT03354637
Drug: ATI-50002 high dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution
Study: NCT03354637
Drug: ATI-50002 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical solution
Study: NCT00232219
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04310332
Drug: 1L-PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational.
Study: NCT04310332
Drug: 4L-PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational.
Study: NCT03236610
Drug: tenofovir monotherapy
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: switching to tenofovir monotherapy
Study: NCT00358150
Drug: Eliglustat tartrate
Normalized name: eliglustat tartrate
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067\[active moiety of eliglustat in plasma\] trough plasma concentration was greater than or equal to \[\>=\]5 nanogram per milliliter \[ng/mL\] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than \[\<\] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
Study: NCT03236610
Drug: tenofovir plus entecavir combination
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuing tenofovir plus entecavir
Study: NCT01192789
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.
Study: NCT03915080
Drug: Oktokog alpha
Normalized name: alpha tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjusting dose and dose interval according to MyPKFIT
Study: NCT01933503
Drug: OCA 10 mg
Normalized name: Ocaliva
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01933503
Drug: OCA 25 mg
Normalized name: Ocaliva
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00003220
Drug: bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00131963
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04375267
Drug: 177Lu-DOTA-TATE + olaparib
Normalized name: DOTA-TATE
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 177Lu-DOTA-TATE in four cycles in combination with escalated doses of olaparib
Study: NCT01047475
Drug: MB-6
Normalized name: MBS
DrugBank: Morpholinylmercaptobenzothiazole (DB14202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6# TID with meal
Study: NCT00485953
Drug: risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: risedronate 35 mg per week
Study: NCT01349413
Drug: Esomeprazole 20mg
Normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Esomeprazole 20mg daily for 8 weeks
Study: NCT02772718
Drug: XOMA 358 single dose level B
Normalized name: Anti-STAT3 B VHH13 single domain antibody
DrugBank: SBT-100 (DB17215)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XOMA 358 single dose level B administered by an intravenous infusion
Study: NCT02772718
Drug: XOMA 358 multiple dose level 1
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XOMA 358 multiple dose level 1 administered by an intravenous infusion
Study: NCT00000177
Drug: Estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01812382
Drug: Retapamulin Microdialysis
Normalized name: Retapamulin
DrugBank: Retapamulin (DB01256)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
Study: NCT03278886
Drug: Low dose naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4.5 mg of low dose naltrexone taken once daily for 8 weeks
Study: NCT03278886
Drug: Nalmefene
Normalized name: Nalmefene
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 18 mg of nalmefene taken once daily for 8 weeks
Study: NCT00301483
Drug: Hemoglobin-based oxygen carrier-201 (HBOC 201)
Normalized name: Hemoglobin-based oxygen carrier 201 is purified, glutaraldehyde-polymerized, bovine hemoglobin, mw 250000
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
Study: NCT00126139
Drug: Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01039350
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa will be initiated at a weekly (QW) subcutaneous dose of 300 mcg over 8 weeks.
Study: NCT00402545
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously on days 1, 8 and 15 of each 21-day cycle for three cycles
Study: NCT00402545
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously on day 1 of each 21-day cycle for 3 cycles
Study: NCT00402545
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenously on day 1 of each 21-day cycle for 3 cycles
Study: NCT00402545
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by continuous infusion pump over a period of 96 hours(dosage wil vary depending upon when participant enrolls in trial)
Study: NCT04071119
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants administer the oxytocin (40 IU) twice a day for 5 - 7 days
Study: NCT00003143
Drug: Amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003143
Drug: DHAP
Normalized name: DHAP
DrugBank: Dihydroxyacetone phosphate (DB04326)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05512728
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: • (titration of 0.05 mg/kg per dose) according to Modified Wilson sedation scale Score to achieve grade 1 (Oriented, eyes may be closed but can respond to 'Can you tell me your name?' 'Can you tell me where you are right now?'
Study: NCT04409522
Drug: The usual treatment
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group will receive the usual treatment of COVID-19
Study: NCT02556905
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
Study: NCT02467322
Drug: Albumin
Normalized name: Albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
Study: NCT02467322
Drug: ascitic fluid
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00671632
Drug: Ramelteon, triazolam, and placebo (56 possible combinations total)
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized sequence over eight consecutive days to include the following:~Ramelteon 16 mg, tablets, orally, one day only;~Ramelteon 80 mg, tablets, orally, one day only;~Ramelteon 160 mg, tablets, orally, one day only;~Triazolam 0.25 mg, capsules, orally, one day only;~Triazolam 0.50 mg, capsules, orally, one day only;~Triazolam 0.75 mg, capsules, orally, one day only;~Ramelteon placebo-matching tablets, orally, one day only, OR Triazolam placebo-matching capsules, orally, one day only;~Additional dose of study medication or placebo, tablets or capsules, orally, one day only.
Study: NCT01044342
Drug: donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule, single oral dose
Study: NCT01309477
Drug: Tacrolimus Sustained-release Capsules (ADVAGRAF)
Normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .
Study: NCT00368862
Drug: Ebixa (memantine hydrochloride)
Normalized name: Bixa orellana seed oil
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00368862
Drug: Cipralex (escitalopram)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00822003
Drug: Oral GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GLP-1 tablet (2mg)
Study: NCT01001780
Drug: Pentostatin; Cyclophosphamide; Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
Study: NCT01614847
Drug: Artificial tears
Normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At random, subjects will receive isotonic artificial tear or a control (normal saline).
Study: NCT02875002
Drug: volasertib
Normalized name: Volasertib
DrugBank: Volasertib (DB12062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib (BI6727) is a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein. Infusion for 60 minutes. Dosing will start at 25 mg/m\^2, is schedule to increase to 100mg/m\^2, and be administered on days 1 and 8 of each 28-day cycle.
Study: NCT02875002
Drug: belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belinostat is a histone deacetylase inhibitor. Infusion will take 30 minutes. Dosing will start at 600 mg/m\^2 , is scheduled to increase to 1000 mg/m\^2, and will be administered on days 1,2,3 and 8,9,10 of each 28-day cycle.
Study: NCT01154062
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib tablet
Study: NCT03376503
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PK,PD and safety assessment
Study: NCT05096676
Drug: Oxytocin: Including placebo
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual received age-dependent dosing of oxytocin and placebo. Participants aged 13-18 years received a dose of 24 IU (3 puffs to each nostril), and younger participants (aged 12 years) received 16 IU.
Study: NCT04065282
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles before radical surgery
Study: NCT04065282
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85mg/m2 Q3W, 3 cycles perioperation
Study: NCT01910883
Drug: Finafloxacin i.v. solution 200 mg
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01910883
Drug: Finafloxacin i.v. solution 400 mg
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01910883
Drug: Finafloxacin i.v. solution 600 mg
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01910883
Drug: Finafloxacin i.v. solution 800 mg
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01910883
Drug: Finafloxacin i.v. solution 1000 mg
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01729728
Drug: Tapentadol
Normalized name: Tapentadol
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapentadol oral solution single dose (1mg/kg body weight)
Study: NCT02397486
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02397486
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02397486
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00462111
Drug: Indometacin
Normalized name: Indometacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01512745
Drug: apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT03621293
Drug: Modulation of Inspired Fraction of Oxygen (FiO2)
Normalized name: OIL OF CAMPHOR
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient.
Study: NCT00796432
Drug: OROS paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00758160
Drug: OROS Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
Study: NCT01975298
Drug: Laquinimod
Normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT00715663
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
Study: NCT04195347
Drug: CM4620
Normalized name: CM4620
DrugBank: CM4620 (DB16466)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT00672958
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Encapsulated immediate-release tablets.
Study: NCT01772563
Drug: volasertib
Normalized name: Volasertib
DrugBank: Volasertib (DB12062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT01772563
Drug: itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsules
Study: NCT03331926
Drug: Xiapex
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up of effect of treatment
Study: NCT03107507
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.
Study: NCT03107507
Drug: Phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
Study: NCT00443209
Drug: Telcagepant 300 mg soft gel capsules
Normalized name: methoxsalen
DrugBank: Telcagepant (DB12228)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule taken orally at onset of migraine
Study: NCT00443209
Drug: Telcagepant 280 mg tablets
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet taken orally at onset of migraine
Study: NCT00624663
Drug: Rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
Study: NCT00179712
Drug: CC-5013
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00179712
Drug: topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00443209
Drug: Rizatriptan 10 mg tablets
Normalized name: rizatriptan 10 MG
DrugBank: Rizatriptan (DB00953)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet taken orally at onset of migraine
Study: NCT00443209
Drug: Placebo to telcagepant capsules
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule taken orally at onset of migraine
Study: NCT00443209
Drug: Placebo to telcagepant tablets
Normalized name: placebo Oral Tablet
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet taken orally at onset of migraine
Study: NCT00443209
Drug: Placebo to rizatriptan tablets
Normalized name: rizatriptan Oral Tablet
DrugBank: Rizatriptan (DB00953)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet taken orally at onset of migraine
Study: NCT03945643
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg administration of sildenafil, one time, one hour prior to measurements.
Study: NCT00210119
Drug: Glivec
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00249093
Drug: oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no